-

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST.

The live webcast may be accessed directly using the following link: https://event.webcasts.com/starthere.jsp?ei=1753938&tp_key=e25fc24c17&tp_special=8. A recording will be made available on the Events page of Tempus’ Investor Relations website.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Tempus Communications
Hanah Heintzelman
Hanah.heintzelman@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
Elizabeth.krutoholow@tempus.com

Industry:

Tempus AI, Inc.

NASDAQ:TEM
Release Versions
English

Contacts

Tempus Communications
Hanah Heintzelman
Hanah.heintzelman@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
Elizabeth.krutoholow@tempus.com

More News From Tempus AI, Inc.

Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electr...

Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568) aimed at accelerating the clinical development and differentiation of an antibody drug conjugate (ADC) program in oncology. Through this collaboration, Daiichi Sankyo will leverage Tempus’ proprietary foundation models and AI expertise, including PRISM2, a state-of-the-art, multimodal foundation model that combines patho...

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Part of...
Back to Newsroom